AcelRx Pharma (ACRX) Completes $10M Common, Warrants Private Placement
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), completed its previously announced private placement of common stock and warrants to purchase common stock on June 1, 2012. Gross proceeds from the offering were approximately $10.0 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes, including the development of the ARX-01 Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AcelRx Pharma (ACRX) Reports Zalviso Phase 3 Met Primary Endpoint
- DryShips (DRYS) Reports Common Stock Offering
- AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!